Stakeholders Eye REMS-Reform Bill As CHIP Offset; Brands Gird For A Fight

By John Wilkerson / August 23, 2017 at 6:18 PM
Stakeholders are pushing the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act as an offset for renewing CHIP funding, multiple industry stakeholders tell Inside Health Policy . The generic lobby plans to step up its advocacy on the bill, but the head of the trade group tells IHP that opponents are girding for a fight over the measure. CREATES would let generic drug companies sue brands to restrain them from blocking access to drug samples needed...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.